Janet Tu, MD
Department of General Oncology, Division of Cancer Medicine
About Dr. Janet Tu
Janet Tu did her undergraduate work at Rice University in Houston, Texas and received her Bachelor of Arts degree in Biochemistry. Afterwards, Dr. Tu received her Doctor of Medicine degree from Baylor College of Medicine followed by completion of Internal Medicine Residency at Baylor College of Medicine. She went on to complete Hematology-Oncology Fellowship program at Baylor Colllege of Medicine. Dr. Janet Tu became board certified in Hematology and Medical Oncology upon completion of fellowship and has served as full time faculty at the University of Texas M.D. Anderson Cancer Center since 2009.
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic, Head, and Neck Medical Oncology (Joint Appointment), The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1999 | Baylor College of Medicine, Houston, Texas, US, Doctor of Medicine |
| 1995 | Rice University, Houston, Texas, US, Bachelor of Arts in Biochemistry |
Postgraduate Training
| 2006-2009 | Clinical Fellowship, Hematology/Medical Oncology, Baylor College of Medicine, Houston, Texas |
| 1999-2002 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2024 | Georgia Composite Medical Board |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Florida Board of Medicine |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2022 | Alabama Board of Medical Examiners |
| 2009 | DEA |
| 2002 | American Board of Internal Medicine |
| 2002 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2023
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2017
Administrative Appointments/Responsibilities
Houston Area Location Section Chief, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Deputy Department Chair, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Houston Area Location Sugar Land Section Chief, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2016 - 2019
Other Professional Positions
Chair, St. Luke's Sugar Land Hospital Ethics Committee, Sugar Land, TX, 2013 - 2020
Member, CHI St. Luke's Health Hospital Sugar Land Peer Review, Sugar Land, TX, 2012 - 2013
Chair, Tumor Board for MD Anderson Cancer Center/CHI St. Luke's Health Hospital Sugar Land, Sugar Land, TX, 2011 - 2013
Extramural Institutional Committee Activities
Value Champion, Thoracic Service Line, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, NCTN LAPS Executive Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member At-Large, Executive Committee of Executive Staff, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Physician Representative, REACH Executive Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Physician Representative, Thoracic Service Line Scheduling Solution- Leadership committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Physician Representative, HAL New Department Work Group, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Physician Representative, Faculty Appeals Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Medical Practice Superintendent, HAL Integration Task Force - Lung Service Line, The University of Texas MD Anderson Cancer Center, 2020 - Present
Physician Representative, HAL Research Expansion Initiative, The University of Texas MD Anderson Cancer Center, 2019 - Present
Physician Representative, Ambulatory Informatics Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Physician Representative, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012
Honors & Awards
| 2024 | Top 10% Provider National Ranking, MD Anderson Cancer Center |
| 2024 | Melvin L. Samuels Award, MDACC Division of Cancer Medicine |
| 2022 | Top 1% Provider National Ranking, MD Anderson Cancer Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Advanced NSCLC: Advanced EGFR. Invited. Texas Lung Conference. Austin, Texas, US.
- 2023. Clinical Trial Partnerships with the Houston Area Locations. Invited. Clinical Research Faculty Learning Series - M.D. Anderson. Houston, Texas, US.
- 2021. Clinical Trial Partnerships with the Houston Area Locations. Invited. Leading Clinical Research Faculty Learning Series - M.D. Anderson. Houston, Texas, US.
- 2020. Speaker. Invited. Clinical Research at the Houston Area Locations Retreat. Houston, Texas, US.
- 2017. Lung cancer, screening, and treatment. Invited. Houston Asian Community Health Fair. Houston, TX, US.
- 2016. Lung Cancer. Invited. Lung Cancer. Houston, TX, US.
Regional Presentations
- 2025. Systemic Therapy Fundamentals: Chemotherapy in 2025 for Lung Cancer. Invited. The Society of Thoracic Surgeons. Los Angeles, CA, US.
- 2024. Chemotherapy in 2025. Invited. The Society of Thoracic Surgeons. San Diego, CA, US.
National Presentations
- 2024. A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. Invited. American Society of Clinical Oncology (ASCO). Chicago, IL, US.
- 2023. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial. Invited. American Society of Clinical Oncology (ASCO). Chicago, IL, US.
- 2022. Identifying MAGE A4 positive tumors for SPEAR T-cell therapies in HLA-A*02 positive patients. Invited. Adaptimmune. New Orleans, LA, US.
Formal Peers
- 2021. Leading Clinical Research Faculty Learning Series - Clinical Trials at the Houston Area Locations. Houston, Texas, US.
Selected Publications
Peer-Reviewed Articles
- Cooper, AJ, Herzberg, B, Parma, M, Wang, K, Alder, L, Weber, UM, Patil, T, Joshi, U, Puri, S, Saqi, A, Clark, P, Gay, CM, Cascone, T, Singhi, EK, Blumenschein, GR, Skoulidis, F, Tu, J, Stinchcombe, TE, Rudin, CM, Shu, CA, Byers, LA, Yu, HA, Zhang, B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41166675.
- Paula AG, Liu X, Karimi A, Concannon K, Heeke S, Elamin YY, Wang K, Pozadzides JV, Vokes N, Tu J, Tsao A, Negrao MV, Zhang J, Singhi E, Zhang B, Rinsurongkawong W, Tran H, Gibbons D, Nilsson M, Heymach JV. Chemotherapy Plus a RET Inhibitor is Associated with Survival Benefit After Progression During a RET Inhibitor Treatment in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report. JTO Clin Res Rep. e-Pub 2025.
- Tu J. Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma showed Promising Systemic and Intracranial Efficacy with Higher Neurologic Toxicity. J Thorac Oncol. e-Pub 2025.
- Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep 6(4):100795, 2025. e-Pub 2025. PMID: 40160974.
- Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol 43(4):403-411, 2025. e-Pub 2025. PMID: 39378386.
- Tsao, A, Hsieh, MH, Koczywas, M, Tu, J, Riess, JW, Tanvetyanon, T, Ma, BT, Zhao, YQ, Redman, MW, Edelman, MJ, Gandara, D, Gray, J, Kelly, K. S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. JTO Clinical and Research Reports 5(12), 2024. e-Pub 2024. PMID: 39619274.
- Wang, T, Navenot, JM, Rafail, S, Kurtis, C, Carroll, M, Van Kerckhoven, M, Van Rossom, S, Schats, K, Avraam, K, Broad, R, Howe, K, Liddle, A, Clayton, A, Wang, R, Quinn, LL, Sanderson, JP, McAlpine, C, Carozza, C, Pimpinella, E, Hsu, SH, Brophy, F, Elefant, E, Bayer, P, Williams, D, Butler, M, Clarke, JM, Gainor, J, Govindan, R, Moreno, V, Johnson, M, Tu, J, Hong, DS, Blumenschein, GR. Identifying MAGE-A4-positive Tumors for TCR T Cell Therapies in HLA-A∗02-eligible Patients. Molecular Therapy Methods and Clinical Development 32(2), 2024. e-Pub 2024. PMID: 38872830.
- Wang, K, Du, R, Myall, NJ, Lewis, WE, Uy, N, Hong, L, Skoulidis, F, Byers, LA, Tsao, A, Cascone, T, Pozadzides, J, Tu, J, Vailati Negrao, M, Gibbons, DL, Park, K, Rinsurongkawong, W, Lee, JJ, Gandara, D, Behl, D, Shu, CA, Riess, JW, Baik, C, Wakelee, HA, Vaporciyan, AA, Heymach, JV, Zhang, J, Le, X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
- Tu J, Altan M. Safety, Tolerability, and Clinical Activity of Selinexor in Combination with Pembrolizumab in Treatment of Metastatic Non-small Cell Lung Cancer. Cancer 129(17):2685-2693, 2023. e-Pub 2023. PMID: 37129197.
- Diaz, EM, Tu, J, Diaz Jr, EM, Antonoff, MB. Lung Cancer Screening in Head and Neck Cancer Patients. Annals of Thoracic Surgery 117(2):305-309, 2023. e-Pub 2023. PMID: 36940898.
- J Wang, Tu J. Severe Radiation-induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep 3(9), 2022. e-Pub 2022. PMID: 36089921.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified Gemcitabine plus Nab-paclitaxel Front-line in Advanced Pancreatic Ductal Adenocarcinoma with Baseline Hyperbilirubinemia. Journal of Gastrointestinal Oncology 11(1):55-60, 2019. e-Pub 2019. PMID: 32175105.
- Ning MS, Dean MK, Taylor KA, Arzu I, Fleming ND, Mutyala N, Suresh P, Lewis MA, Tu J, Hassid VJ, Joe T, Byler C, Bloom ES, Shah S. Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention. Cureus 11(5):e4583, 2019. e-Pub 2019. PMID: 31309008.
Other Articles
- Elamin Y, Heeke S, Negrao M, Fossella F, Byers L, Zhang J, Gay C, Tu J, Pozadzides J, Tran H, Le X, Feng L, Blumenschein G, Tsao A, Heymach AJ Efficacy and Safety of Osimertinib Plus Alisertib or Sapanisertib in Osimertinib-Resistant EGFR-Mutant NSCLC: Results from a Phase 1b Clinical Trial. Clin Cancer Res.
- Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy (Nature Communications, (2022), 13, 1, (1970), 10.1038/s41467-022-29539-3). Nature Commun 15(1), 2024. PMID: 38965214.
- Mohammad Z, Mitchell KG, Nelson DB, Robb C, Jreissaty C, Tu J, Vaporciyan AA, Sepesi B, Antonoff MB Lung Cancer Patient Perceptions of the Value of an Outreach Thoracic Surgical Clinic. Ann Thorac Surg 108(2):358-362, 2019. PMID: 30928553.
- Mutayala N, Mutayala R, Lewis M, Tu J, Taylor K, Desai S, Buck S, Reed V, and Shah S Describing the Use of a Cost-Effective Online Tool to Qualify the Geographic Location of Patients Served by an Outpatient Oncology Center. Journal of Cancer Prevention and Current Research 6(2), 2016.
- Tu JC, Tsao AS, Koczywas M, Riess JW, Tanvetyanon T, Ma B, Ming-Hui H, Zhao Y, Redman M, Edelman M, Gandara D, Kelly K, Gray J A Randomized Phase II Trial of Carboplatin-Paclitaxel with and without Ramucirumab in Patients with Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. J Thorac Oncol.
Abstracts
- Lin SH, Liu Y, Gupta P, Tidwell BS, Thall PF, Chun SG, Chang JY, Liao Z, Lee Z, Marcondes M, Tagliaferri M, Zalevsky J, Blumenschein G, Heymach JV, Altan M, Tu J. REStoring lymphoCytes Using NK TR-255 after chemoradiothEapy in solid tumors (RESCUE). European Society for Medical Oncology (ESMO) 18(11):S298-S299, 2023. e-Pub 2023.
- Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff M, Le X, Tu JC, Pek M, Poh J, Ngeow KC, Tsao AS, Cascone T, Negrao MV, Blumenschein GR, Heymach J, Elamin YY. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial. J Clin Oncol 41(16), 2023. e-Pub 2023.
Patient Reviews
CV information above last modified July 22, 2026